6533b820fe1ef96bd1279210

RESEARCH PRODUCT

Resistance to third-generation cephalosporins in Escherichia coli in the French community: The times they are a-changin'?

J. LeroyHélène BouxomAudrey JeanvoineXavier BertrandHoussein Gbaguidi-haoreC. Slekovec

subject

0301 basic medicineMicrobiology (medical)Veterinary medicinemedicine.drug_classeducationResistance030106 microbiologyCephalosporinAntibioticsContext (language use)Microbial Sensitivity TestsQuinolonesmedicine.disease_causebeta-LactamasesThird generation cephalosporins03 medical and health sciencesNalidixic Acid0302 clinical medicineAntibiotic resistanceCiprofloxacinDrug Resistance BacterialOutpatientsmedicineEscherichia coliPrevalenceHumansPharmacology (medical)030212 general & internal medicineAntibiotic useEscherichia coliComputingMilieux_MISCELLANEOUSEscherichia coli InfectionsRetrospective StudiesResistance (ecology)business.industryThird-generation cephalosporinsGeneral Medicine3. Good healthAnti-Bacterial AgentsCephalosporins[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious Diseases[SDE]Environmental SciencesFrancebusiness

description

Since the early 2000s, Escherichia coli resistance to third-generation cephalosporins (3GCs) has been increasing in all European countries, mainly due to the spread of extended spectrum β-lactamases (ESBLs). Here we present a retrospective study that combines resistance of E. coli to 3GCs and quinolones with data on antibiotic use in the community in a region of Northeastern France.Since 2012, an observational surveillance of antimicrobial resistance and antibiotic use in the community was conducted: data on antimicrobial resistance in E. coli isolates were collected from 11 private laboratories, and consumption data were collected from the three main healthcare insurances.A significant decrease in the prevalence of resistance to 3GCs (from 5.6% to 4.2%; P0.001), nalidixic acid (from 16.7% to 14.8%; P = 0.004) and ciprofloxacin (from 10.9% to 8.1%; P0.001) was reported between 2015 and 2017. Although total antibiotic consumption did not vary significantly between 2012 and 2017, a decrease in the consumption of 3GCs (-32.%; P0.001) and quinolones (-25.5%; P0.001) was observed.Here we report a decrease in the prevalence of E. coli isolates resistant to 3GCs and quinolones in outpatients in the context of significant decreasing consumption of these two antibiotic classes.

10.1016/j.ijantimicag.2020.105909https://pubmed.ncbi.nlm.nih.gov/31991220